CHIEF: A retrospective self‐control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis
Emicizumab resulted in an improved ABR compared to CFC, especially for joint and spontaneous bleeds, had fewer administration complications, and was substantially less expensive compared to CFC prophylaxis; however, more research is necessary for a complete understanding of the effect of emicizumab on joint health and muscle bleeds.
Authors
- Guy A. Young (ORCID: https://orcid.org/0000-0001-6013-1254)
- Susan Knight
- Daniel Mashiach (ORCID: https://orcid.org/0000-0002-4025-7412)
- Jemily Malvar (ORCID: https://orcid.org/0000-0002-5481-6780)
- Kendall Carneiro
- Patrice Mead
Institutions
- University of Southern California (US)
- Children's Hospital of Los Angeles (US)
- Western University of Health Sciences (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1002/pbc.31351
- Citations
- 3
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36